SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, HorseShoe Man
Search This Board:
Last Post: 8/31/2015 4:51:57 PM - Followers: 565 - Board type: Free - Posts Today: 0

MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Outstanding shares 5,000,948,700 as of Jul 8, 2015 

Office: (401) 762-0045  |  Email:

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 Therapeutic Candidate  


    Discovery Optimization    

    Preclinical Development    

    Phase 1    

    Phase 2/b   

    Phase 3    



yes yes yes yes  



yes yes      



yes yes      



yes yes      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations

W. Gerald Newmin, Chairman and Chief Executive Officer

Dr. Steve Chang Ph. D., Director

Grant Miller, Director


Alan Tuchman, M.D.

Thomas A. Page, Director

Edward Sigmond, Director


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:10:34 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:09:13 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:07:11 PM
MCET News: Statement of Changes in Beneficial Ownership (4) 07/30/2015 06:05:40 PM
MCET News: Quarterly Report (10-q) 07/16/2015 06:06:29 AM
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#40738   Under the terms of the agreement, OXIS paid Dip66 08/31/15 04:51:57 PM
#40737   I hear you on that adding shares at Dip66 08/31/15 03:35:43 PM
#40736   Look we need to see more increases in The dead cat bouncer 08/31/15 02:06:05 PM
#40735   1.8M bought $MCET. Something must be in the Dip66 08/31/15 12:20:31 PM
#40734   should be a very interesting week. Imho HorseShoe Man 08/31/15 08:38:46 AM
#40733   Great to see MultiCell is generating significant revenue Dip66 08/29/15 10:21:15 AM
#40732   There's a hole bunch of eyes on MCET HorseShoe Man 08/29/15 07:49:19 AM
#40731   Horse . . bontooth 08/29/15 03:50:30 AM
#40730   they are current read the 10 q. The dead cat bouncer 08/28/15 12:12:46 PM
#40728   maybe I'm wrong but I'm not taking my HorseShoe Man 08/28/15 11:09:07 AM
#40727   Yea volume is astronomical. It's like a blitzkrieg starkd748 08/28/15 11:04:25 AM
#40726   No kidding, it not man people that can ctvette2003 08/28/15 11:00:04 AM
#40725   Yea building lots of investors so many look starkd748 08/28/15 10:54:57 AM
#40724   When this starts it's gone. I believe they HorseShoe Man 08/28/15 10:43:22 AM
#40723   Blowing past the 4's today imho HorseShoe Man 08/28/15 10:34:29 AM
#40722   The medical technology and pharma patent space is Dip66 08/28/15 10:34:26 AM
#40721   Ok what the hell are you looking at, ctvette2003 08/28/15 10:09:29 AM
#40720   Not sure myself just yet but looks like HorseShoe Man 08/28/15 09:45:23 AM
#40719   What am I missing Horse? ctvette2003 08/28/15 09:29:28 AM
#40718   What the heck just happened to MCET this HorseShoe Man 08/28/15 09:18:46 AM
#40717   I doubt that would be like buyin sln# starkd748 08/28/15 02:50:00 AM
#40716   Good video clip! Dip66 08/27/15 09:13:39 PM
#40715   MultiCell Immuno Therapeutics, The leader bontooth 08/27/15 06:16:14 PM
#40714   someone is taking a position. The dead cat bouncer 08/27/15 04:35:05 PM
#40713   Something must be brewing! Dip66 08/27/15 03:39:23 PM
#40712   nice volume today. Moving up again. The dead cat bouncer 08/27/15 02:32:31 PM
#40711   great more bid support The dead cat bouncer 08/26/15 12:17:29 PM
#40710   Holding out for .0001's at this point Dip66 08/24/15 03:54:05 PM
#40709   not buying into MCET anymore bontooth 08/22/15 02:45:16 AM
#40708   ok good, I was trying to find out bontooth 08/22/15 01:38:14 AM
#40707's like MCET is the pizza company that Glitch07 08/20/15 06:35:04 PM
#40706   If MCET doesn't get any profits from oxis HorseShoe Man 08/20/15 08:32:53 AM
#40705   Like saying you own a pizza company and HorseShoe Man 08/19/15 09:03:34 PM
#40704   maybe. but how much of future revenue does bontooth 08/19/15 07:59:27 PM
#40703   doesn't that mean MCET will receive 10 million HorseShoe Man 08/19/15 10:36:51 AM
#40702   It does appear that Oxis along with the bontooth 08/19/15 10:10:24 AM
#40701   my hat's off to that . . bontooth 08/19/15 09:54:36 AM
#40700   Your right. There's no trials yet that we HorseShoe Man 08/18/15 04:49:46 PM
#40699   There are no trials. Good luck! I am simon wagstaff 08/18/15 12:56:01 PM
#40698   Sure would be nice if OXIS went to HorseShoe Man 08/18/15 12:00:05 PM
#40697   I don't think MCET will get much attention Dip66 08/16/15 05:28:21 PM
#40696   GET READY FOR THE NEWS SOON. Anytime. NILDIP007 08/13/15 03:30:35 PM
#40695   Amateur hour, with 5B O/S this will get Dip66 08/13/15 02:18:34 PM
#40694   Generally the MM pass this back and forth simon wagstaff 08/13/15 12:23:48 PM
#40693   There is some buying going on. SHHHHHH! The dead cat bouncer 08/13/15 10:52:03 AM
#40692   Once I get in I would love for HorseShoe Man 08/12/15 12:53:38 PM
#40691   Trials for what? The big picture clearly includes deception. simon wagstaff 08/09/15 07:42:24 AM
#40690   Your clearly missing the big picture, trial news Jeppy D 08/08/15 10:06:45 AM
#40689   Amazing how some have time to participate Dip66 08/07/15 11:09:08 PM
#40688   "MCET/OXIS trial news is expected" simon wagstaff 08/07/15 04:38:39 PM